Non-Small Cell Lung Cancer (NSCLC)

Protocol AMP-024

AMP-024 is a single arm Phase II study to assess the efficacy of the combination of AmplimexonŽ with TaxotereŽ (docetaxel) in patients with previously treated NSCLC.  It is currently under development.  Further information on this protocol will be available in the near future.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Further information

For more information on AMP-024 or to find the clinical trial site nearest you, please click here.